13F Holdings
中文EN

AXSM Axsome Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1579428 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY54.2%
TTM net income YoY31.5%
TTM EPS YoY35.1%
Revenue 3-yr CAGR57.0%
Net income 3-yr CAGR—

Margins

Gross margin93.2%
Operating margin-17.5%
Net margin-18.2%
FCF margin-9.5%
EBITDA margin-17.4%

Returns

ROE-175.6%
ROA-21.0%
ROIC (approx.)—
Asset turnover1.16x

Leverage & solvency

Liabilities / assets87.2%
Debt / equity1.78x
Current ratio1.42x
Interest coverage22.43x

Cash quality & payout

Operating cash flow / net income0.52x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$259.69M$218.38M$191.20M$196.00M$170.99M$150.04M$121.46M$118.77M
Cost of revenue$17.80M$13.56M$14.72M$12.33M$11.91M$13.45M$9.79M$10.51M
Gross profit$241.89M$204.81M$176.48M$183.67M$159.08M$136.59M$111.67M$108.25M
R&D expense$50.62M$46.23M$52.68M$48.79M$40.16M$49.54M$44.78M$55.01M
SG&A expense$203.11M$208.14M$185.00M$169.30M$150.24M$130.28M$120.79M$113.27M
Operating income-$11.07M-$49.65M-$63.36M-$26.96M-$46.11M-$36.71M-$56.98M-$72.62M
Interest expense-$3.42M-$3.20M$3.09M-$3.21M-$3.38M-$4.09M$5.26M-$5.43M
Pretax income-$12.79M-$51.19M-$64.54M-$28.13M-$47.23M-$48.93M-$59.41M-$74.83M
Income tax$88,000$128,000$0$430,000$0-$960,000$0$85,000
Net income-$12.88M-$51.31M-$64.54M-$28.56M-$47.23M-$47.97M-$59.41M-$74.91M
EBITDA-$10.94M-$49.50M-$63.24M-$26.84M-$45.99M-$36.59M-$56.83M-$72.49M
EPS (basic)-0.25-0.99-1.26—-0.94-0.97-1.22—
EPS (diluted)-0.25-0.99-1.26—-0.94-0.97-1.22—
Weighted avg. shares (diluted)52.45M51.80M51.20M—50.02M49.44M48.87M—
Balance sheet
Cash & equivalents$313.86M$319.85M$305.11M$322.93M$325.27M$303.02M$300.91M$315.35M
Receivables$343.11M$277.46M$251.06M$224.46M$196.51M$198.82M$161.40M$142.00M
Inventory$42.58M$37.88M$31.52M$27.94M$23.77M$18.44M$16.32M$15.73M
Current assets$724.64M$656.57M$611.21M$588.99M$565.34M$536.62M$494.63M$485.06M
PP&E, net$943,000$874,000$567,000$562,000$605,000$667,000$773,000$584,000
Goodwill$12.04M$12.04M$12.04M$12.04M$12.04M$12.04M$12.04M$12.04M
Intangibles$35.75M$37.36M$38.95M$40.52M$42.13M$43.73M$45.32M$46.89M
Total assets$826.77M$761.45M$713.61M$689.80M$669.25M$639.78M$596.67M$568.50M
Current liabilities$509.72M$460.45M$439.21M$378.84M$360.29M$342.10M$243.91M$230.10M
Short-term debt$70.00M$70.00M$70.00M$70.00M$70.00M$70.00M—$0
Long-term debt$118.07M$117.96M$117.85M$117.75M$117.64M$117.54M$181.38M$180.71M
Total debt$188.07M$187.96M$187.85M$187.75M$187.64M$187.54M$181.38M$180.71M
Total liabilities$721.34M$678.14M$659.02M$601.51M$595.52M$566.71M$543.47M$511.48M
Shareholders' equity$105.43M$83.30M$54.59M$88.30M$73.73M$73.08M$53.20M$57.02M
Net debt-$125.79M-$131.89M-$117.26M-$135.19M-$137.63M-$115.48M-$119.53M-$134.64M
Shares outstanding52.58M52.30M51.42M50.88M50.31M49.82M49.22M48.67M
Cash flow statement
Operating cash flow-$9.47M-$32.95M-$20.70M-$18.65M$1.05M-$32.42M-$43.38M-$26.20M
Capital expenditure$197,000$450,000$121,000$71,000$58,000$13,000$338,000$30,000
Free cash flow-$9.67M-$33.40M-$20.82M-$18.72M$988,000-$32.44M-$43.71M-$26.23M
Investing cash flow-$197,000-$450,000-$121,000-$71,000-$58,000-$13,000-$338,000-$30,000
Financing cash flow$3.67M$48.15M$2.99M$16.39M$21.27M$34.54M$29.27M$14.24M
Depreciation & amortization$128,000$143,000$116,000$114,000$120,000$120,000$149,000$129,000
Stock-based compensation$26.36M$27.15M$23.44M$22.73M$23.10M$24.61M$23.31M$21.99M

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.